A Study to Learn About How Loss of Liver Function Affects the Blood Levels of the Study Medicine Called PF-07817883.
COVID-19
About this trial
This is an interventional basic science trial for COVID-19 focused on measuring Hepatic Impairment, COVID-19
Eligibility Criteria
Inclusion Criteria: (HI Cohorts Only): Stable HI that meets criteria for Class A or B of the Child-Pugh classification; (all Cohorts): BMI of 17.5 to 38.0 kg/m2 Exclusion Criteria: Any condition possibly affecting drug absorption Additional Exclusion Criteria for HI Cohorts Only Limited predicted life expectancy Hepatic dysfunction secondary to acute ongoing hepatocellular process. Signs of clinically active Grade 2, 3 or 4 hepatic encephalopathy. Severe ascites and/or pleural effusion History of kidney, liver, or heart transplantation. Persistent severe, uncontrolled hypertension.
Sites / Locations
- Anaheim Clinical Trials, LLCRecruiting
- National Institute of Clinical ResearchRecruiting
- Catalina Research Institute, LLCRecruiting
- Research Centers of America ( Hollywood )Recruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Experimental
Experimental
Experimental
Cohort 1
Cohort 2
Cohort 3
Cohort 4
No hepatic impairment
Mild hepatic impairment
Moderate hepatic impairment
Severe hepatic impairment